Deltec Asset Management LLC Aeglea Bio Therapeutics, Inc. Transaction History

Deltec Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 27, 2020	SELL	$7.23 - $8.55 $180,525 - $213,484	-24,969 Closed	0 $0
Q3 2019 Oct 24, 2019	SELL	$6.42 - $9.0 $146,985 - $206,055	-22,895 Reduced 47.83%	24,969 $192,000
Q2 2019 Jul 29, 2019	BUY	$6.1 - $8.78 $58,560 - $84,288	9,600 Added 25.09%	47,864 $328,000
Q4 2018 Jan 23, 2019	SELL	$6.51 - $10.19 $337,445 - $528,198	-51,835 Reduced 57.53%	38,264 $287,000
Q3 2018 Oct 18, 2018	SELL	$8.24 - $11.0 $508,259 - $678,502	-61,682 Reduced 40.64%	90,099 $862,000
Q2 2018 Aug 07, 2018	BUY	$7.87 - $10.89 $1.19 Million - $1.65 Million	151,781 New	151,781 $1.61 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Deltec Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Deltec Asset Management LLC with notifications on news.